Closure of Trading Window
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday, February 8, 2018, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2017.... Board Meeting On February 8, 2018
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday, February 8, 2018, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2017.... Press Release / Media Release
Sub: Glenmark Pharmaceuticals Presents Preliminary Biomarker Data on GBR 1302, a HER2xCD3 Bispecific Monoclonal Antibody, at the ASCO-SITC Clinical Immuno-Oncology Symposium With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Request you to kindly take the same on record. Shareholding for the Period Ended December 31, 2017
Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017. For more details, kindly Click here Press Release / Media Release
To, Dy. General Manager, Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai - 400 001. Ref: Scrip Code: 532296 Dear Sirs, Sub: Glenmark initiates Phase IIb dose range finding study for novel molecule GRC 27864... Statement Of Investor Complaints As On December 31, 2017
Pursuant to Regulation 13 (3) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find attached statement of Investor complaints for the quarter ended December 31, 2017. Press Release / Media Release
January 10, 2018 To, To, Dy. General Manager The Manager - Listing, Department of Corporate Services, The National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai - 400 001. Bandra (E), Mumbai - 400 051.... Glenmark Pharmaceuticals: A healthy bet
Focus on low-risk complex generics and speciality products are key positives Press Release / Media Release
Glenmark Pharmaceutical launches the biosimilar of Adalimumab in India With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Request you to kindly take the same on record. Indian pharma sees traction in novel biologics
While Glenmark is betting on its biologic for atorpic dermatitis, Biocon was the first to develop and introduce two novel biologics in the Indian market